CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on...
Day: April 24, 2025
Cronos Group Inc. to Hold 2025 First Quarter Earnings Conference Call on May 8, 2025
TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold...
Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting
CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
X4 Pharmaceuticals Announces Reverse Stock Split
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people...
Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
>8,500 samples and 100 million cells of high resolution and fully annotated spatial proteomics data availableMARLBOROUGH, Mass., April 24, 2025...
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
April 28th AUA data presentation to highlight study in patients with high-grade non-muscle invasive bladder cancer (HG-NMIBC) Virtual event to be...
Autonomize AI Prior Authorization Copilot: Helping Patients Get Care Faster, Safer, and with Less Stress
AUSTIN, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Autonomize AI, the leader in healthcare-native AI, today announced a major update...
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
ADC assay now available through ABS; customer study proves IO60 is a spatial workhorseMARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE)...
ORYZON Raises €30 Million in Capital Increase
Issued 12,765,958 new sharesPriced at €2.35 per share, representing a 15.44% discount on the 5-day VWAPStrong investor demand, with the...
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status
WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company...
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025
TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from...
Nerve Renew Under Review & Ingredients Guide | Best Nerve Pain Supplement Explained
Nerve Renew is a dietary supplement formulated to support nerve health, particularly for individuals experiencing symptoms of peripheral neuropathy such...
Tonic Greens Review: Will TonicGreens Supplement Work for Immune Support? Read Tonic Greens Official Report!
Tonic Greens is a dietary supplement formulated with a blend of natural superfoods, antioxidants, and immune-supporting ingredients. It's often promoted...
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™
(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer patientTreatment...
Kura Oncology to Report First Quarter 2025 Financial Results
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed...
Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
Funding supports the commercial product development of VisioLite® Device and Laser Scleral Microporation Human Clinical Study. Capital raised to date...
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully...
Amwell® to participate in upcoming investor conferences
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled...
SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago
Two PROTAC synergy using two E3 ligases for achieving levels of degradation of KRAS G12D not achieved with single PROTACs,...
Avidicure Launches with $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer
AVC-Boosters are designed as dual agonistic antibodies to safely deliver targeted and potent monotherapy with broad application in oncology Lead...